M
Maarten Naesens
Researcher at Katholieke Universiteit Leuven
Publications - 272
Citations - 11034
Maarten Naesens is an academic researcher from Katholieke Universiteit Leuven. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 48, co-authored 221 publications receiving 8130 citations. Previous affiliations of Maarten Naesens include The Catholic University of America & California Pacific Medical Center.
Papers
More filters
Journal ArticleDOI
Calcineurin Inhibitor Nephrotoxicity
TL;DR: The authors critically review the current evidence relating systemic blood levels of cyclosporine and tacrolimus to calcineurin inhibitor nephrotoxicity, and summarize the data suggesting that local exposure to cycloporine or tacolimus could be more important than systemic exposure.
Journal ArticleDOI
The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials
Mark Haas,Alexandre Loupy,Carmen Lefaucheur,Candice Roufosse,Denis Glotz,Daniel Serón,Brian J. Nankivell,Philip F. Halloran,Robert B. Colvin,Enver Akalin,Nada Alachkar,Serena M. Bagnasco,Yassine Bouatou,Yassine Bouatou,Jan U. Becker,Lynn D. Cornell,J.-P. Duong Van Huyen,Ian W. Gibson,Edward S. Kraus,Roslyn B. Mannon,Maarten Naesens,Volker Nickeleit,Peter Nickerson,Dorry L. Segev,Harsharan K. Singh,Mark D. Stegall,P. Randhawa,Lorraine C. Racusen,Kim Solez,Michael Mengel +29 more
TL;DR: The Banff ABMR criteria are updated and paves the way for the Banff scheme to be part of an integrative approach for defining surrogate endpoints in next‐generation clinical trials.
Journal ArticleDOI
The Banff 2019 Kidney Meeting Report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection
Alexandre Loupy,Mark Haas,Candice Roufosse,Maarten Naesens,Benjamin Adam,Marjan Afrouzian,Enver Akalin,Nada Alachkar,Serena M. Bagnasco,Jan U. Becker,Lynn D. Cornell,Marian C. Clahsen-van Groningen,Anthony J. Demetris,Duska Dragun,Jean-Paul Duong Van Huyen,Alton B. Farris,Agnes B. Fogo,Ian W. Gibson,Denis Glotz,Juliette Gueguen,Zeljko Kikic,Nicolas Kozakowski,Edward S. Kraus,Carmen Lefaucheur,Helen Liapis,Roslyn B. Mannon,Robert A. Montgomery,Brian J. Nankivell,Volker Nickeleit,Peter Nickerson,Marion Rabant,Lorraine C. Racusen,Parmjeet Randhawa,Blaise Robin,Ivy A. Rosales,Ruth Sapir-Pichhadze,Carrie A. Schinstock,Daniel Serón,Harsharan K. Singh,Rex Neal Smith,Mark D. Stegall,Adriana Zeevi,Kim Solez,Robert B. Colvin,Michael Mengel +44 more
TL;DR: This report on kidney transplant pathology details clarifications and refinements to the criteria for chronic active (CA) T cell–mediated rejection, borderline, and antibody‐mediated rejection (ABMR).
Journal ArticleDOI
Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients
TL;DR: The MRP2 C-24T and C-3972T polymorphisms protect renal transplant recipients from a decrease in MPA exposure associated with mild liver dysfunction and are suggested to be associated with a lower oral clearance of MPA in steady-state conditions.
Journal ArticleDOI
CYP3A5 and CYP3A4 but not MDR1 Single-nucleotide Polymorphisms Determine Long-term Tacrolimus Disposition and Drug-related Nephrotoxicity in Renal Recipients
TL;DR: The lack of a time‐related increase in dose‐corrected tacrolimus exposure observed with the CYP3A4*1/CYP3A5*1 and CYP6*1B/Cyp3A 5*1 genotypes is associated with tac rolimus‐related nephrotoxicity, possibly as a result of higher concentrations of toxic metabolites.